UroGen Reports $68M Q3 ZUSDURI Revenue, 35% YoY Growth
UroGen's ZUSDURI generated $68M in revenue in Q3 2026, while the FDA accepted the NDA for UGN-103 for review with a PDUFA goal date of June 14, 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed